AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease

The primary goal of this clinical trial is to evaluate the efficacy of AST-120 (Kremezin®) in combination with standard care in reducing the levels of protein-bound uremic toxins (PBUTs), specifically indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), in patients with acute kidney disease (AKD). The trial aims to assess whether AST-120 can prevent further renal deterioration and slow the progression from AKD to chronic kidney disease (CKD) by mitigating the accumulation of PBUTs. Additionally, the study will investigate the potential of AST-120 to reduce the risk of CKD-associated complications, including cardiovascular disease, by reducing PBUT levels in AKD patients.

NCT Number	NCT07182422
Lead Sponsor	Chang Gung Memorial Hospital Collaborators: Conmed Pharmaceutical & Bio-Medical Corporation
Conditions	Acute Kidney Disease, Acute Kidney Injury (AKI)
Enrollment	100 participants
Start Date	2025-09-15
Primary Completion	2027-02-11 (estimated)
Study Completion	2027-03-13 (estimated)
Updated on ClinicalTrials.gov	2025-09-19